MannKind Corporation

    Jurisdiction
    United States
    LEI
    213800GFBCNY1ZFST722
    ISIN
    US56400P7069 (MNKD)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    InsiderPie Expert Score
    51 / 100
    Even with peer group:
    50 / 100
    Fair value (Benjamin Graham formula)
    €5.15 9.9% undervalued
    Financial strength (Piotroski F-Value)
    8 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    5 / 7

    Profile

    MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. Read full profile

    Fundamentals

    Net revenue
    €257.37M
    Gross margin
    74.9%
    EBIT
    €57.02M
    EBIT margin
    22.2%
    Net income
    €27.98M
    Net margin
    10.9%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €313.41M +21.8% €24.83M -11.2%
    €366.17M +16.8% €49.99M +101.3%
    €401.10M +9.5% €70.21M +40.5%

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Binder Steven B. N/A -75K $3.94 -$296.95K
    Thomson David EVP Genl Counsel & Secretary -7.5K $3.94 -$29.42K

    Earnings Calls

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 1.6M $8.30M +668K Buy

    Earnings Calls

    Latest earnings call: May 8, 2024 (Q1 2024)

    Add to watchlist

    Notifications